Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Nontargeted Approaches for Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Datopotamab deruxtecan recently received accelerated approval from the FDA for which indication?**
   a. Previously untreated EGFR wild-type metastatic non-small cell lung cancer (mNSCLC)
   b. EGFR wild-type mNSCLC previously treated with platinum chemotherapy
   c. Previously untreated EGFR-mutant mNSCLC
   d. EGFR-mutant mNSCLC previously treated with an EGFR-directed therapy and platinum-based chemotherapy

2. **Which of the following biomarkers has demonstrated a potential use in predicting response to datopotamab deruxtecan?**
   a. Tumor mutational burden
   b. PD-L1 tumor proportion score
   c. TROP2 mRNA overexpression
   d. TROP2 NMR (normalized membrane ratio) measured by quantitative continuous scoring

3. **The ongoing Phase III eVOLVE-Lung02 trial is evaluating chemotherapy in combination with which of the following agents as first-line therapy for patients with mNSCLC and tumor cell PD-L1 expression lower than 50%?**
   a. Datopotamab deruxtecan
   b. Ivonescimab
   c. Volrustomig
   d. Sabestomig

4. **Which of the following is the best mechanistic description of acasunlimab?**
   a. A HER2-directed antibody-drug conjugate
   b. An anti-PD-1 monoclonal antibody
   c. A bispecific antibody targeting PD-L1 and 4-1BB
   d. A bispecific antibody targeting PD-1 and TIGIT

5. **What was the most commonly observed adverse event among patients who received acasunlimab and pembrolizumab in a Phase II clinical trial?**
   a. Pyrexia
   b. QT interval prolongation
   c. Dyspnea
   d. Liver-related events